-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $115 Price Target

Benzinga·09/02/2026 17:22:38
Listen to the news
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $115 price target.